Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1100959
PUBLISHER: GlobalData | PRODUCT CODE: 1100959
Immuno-Oncology - Thematic Research
PUBLISHED:
PAGES: 167 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer
Checkpoint modulation is the most valuable IO sector
Within 2021-2022, the next immuno-oncology breakthrough has not happened
High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs
Scope
- Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders and payers.
- Key topics covered for IO in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II - III).
- Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
- Robust analysis of high-prescriber survey conducted with 80 oncologists.
Reasons to Buy
- What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
- What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
- How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
- What is the regulatory landscape for IO agents in the US, the 5EU Japan, and China?
- What is the current and future outlook of IO according to high prescribers?
Product Code: GDHCHT328
Table of Contents
Table of Contents
1. Preface
- 1.1. Table of Contents
- 1.2. Abbreviations
- 1.3. Related Reports
2. Executive Summary
- 2.1. Key Findings
3. Immuno-oncology Overview
- 3.1. What is Immuno-oncology?
- 3.2. Most Important Milestones of Immuno-oncology Development Globally
- 3.3. Key Twitter Chat
4. Trends
- 4.1. Industry Trends - Bispecific Antibodies
- 4.2. Industry Trends - Cancer Vaccines
- 4.3. Industry Trends - Cell Therapies
- 4.4. Industry Trends - Checkpoint Modulators
- 4.5. Industry Trends - Cytokines
- 4.6. Industry Trends - Oncolytic Viruses
- 4.7. Regulatory Trends
5. Value Chain
- 5.1. Immuno-oncology Value Chain
- 5.2. Bispecific Antibodies
- 5.3. Cancer Vaccines
- 5.4. Cell Therapies
- 5.5. Checkpoint Modulators
- 5.6. Cytokines
- 5.7. Oncolytic Viruses
- 5.8. Immuno-oncology in Clinical Trials
6. Marketed Products
- 6.1. Marketed Immuno-oncology Products in the 8MM
- 6.2. Total Market Size for Immuno-oncology Agents
- 6.3. Ten Highest-grossing Immuno-oncology Treatments in 2021
- 6.4. Leading Checkpoint Modulators in The 8MM
- 6.5. Leading Cancer Vaccines, Bispecific Antibodies and Oncolytic Viruses in The 8MM
- 6.6. Leading Cell Therapies in The 8MM
7. Pipeline Products
- 7.1. Immuno-oncology Pipeline Products in the 8MM
- 7.2. Pipeline Products by Type and Phase
- 7.3. Future Outlook of Immuno-oncology Agents According to High-Prescribing Physicians
- 7.4. Consensus Forecast Sales for the Top Products per Class of Immuno-oncology
- 7.5. Late Stage Bispecific Antibody Products
- 7.6. Late Stage Cancer Vaccine Products
- 7.7. Late Stage Cell Therapy Products
- 7.8. Late Stage Checkpoint Modulator Products
- 7.9. Late Stage Cytokine Products
- 7.10. Late Stage Oncolytic Virus Products
8. Market Analysis and Deals
- 8.1. Immuno-oncology Market Analysis and Forecast by Class of Therapy
- 8.2. Top 10 Strategic Partnership Deals by Size in the Immuno-oncology Space
- 8.3. Latest Strategic Partnership Deals in the Immuno-oncology Space
- 8.4. Mergers and Acquisitions That Include Immuno-oncology Assets: 2020 - 2021
- 8.5. Mergers and Acquisitions That Include Immuno-oncology Assets: 2016 - 2020
9. Regulatory and Market Access
- 9.1. Immuno-oncology in Clinical Trials
- 9.2. Differences in Immuno-oncology Clinical Trials - KOLs Perspective
- 9.3. Challenges in Immuno-oncology Clinical Trials - KOLs Perspective
- 9.4. Regulatory and Market Access - US
- 9.5. Regulatory and Market Access - Europe
- 9.6. Regulatory and Market Access - Japan
- 9.7. Regulatory and Market Access - China
- 9.8. Comparison of Early Access Schemes in the US, EU, Japan, and China
- 9.9. Barriers to Access According to High Prescribers
10. Opportunities, Challenges, and Unmet Needs
- 10.1. Bispecific Antibodies - Opportunities & Challenges
- 10.2. Cancer Vaccines - Opportunities & Challenges
- 10.3. Cell Therapies- Opportunities & Challenges
- 10.4. Checkpoint Modulators - Opportunities & Challenges
- 10.5. Cytokines - Opportunities & Challenges
- 10.6. Oncolytic Viruses - Opportunities & Challenges
- 10.7. Clinical Unmet Needs in Immuno-oncology - Gap Analysis
- 10.8. Commercial Unmet Needs in Immuno-oncology - Gap Analysis
- 10.9. Unmet Needs - KOLs Perspective
- 10.10. Unmet Needs According to High Prescribers
- 10.11. R&D Strategies
- 10.12. Opportunities According to KOLs and Closing Remarks
11. Companies
12. Appendix
- 12.1. Sources
- 12.2. Primary Research
- 12.3. Key Themes Impacting the Pharmaceutical Industry
- 12.4. Our Thematic Research Methodology
- 12.5. About the Authors
- 12.6. Contact Us
- 12.7. Disclaimer
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.